Jeremy Ramdial

Stem Cell Transplant and Cellular Therapy. Tweets, Retweets, and Likes are based on my own opinion and not medical advice.

[Fadi Haddad, MD @FadiHaddad_MD]

What is Measurable Residual Disease #MRD❓

🟰 Hidden part of the iceberg ❄️

👀 Minimal disease left behind leading to disease relapse 🤕

💊 New strategies available to treat MRD and cure #Leukemia 👊

#bloodcancer #cancerawareness #endcancer

[Jeremy Ramdial @Jeremy_Ramdial]

Congrats Rohtesh Mehta!! of @MDAndersonNews on
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide https://t.co/pKDo3wK0Ji

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

Dr. Garcia-Manero and @DrHKantarjian discuss the VERONA trial at #SOHO2025. Stay tuned for more at SOHO Insider

[Daniel Auclair @AuclairDan]

Dr. Uday Popat @SOHO25 . HCT still has an important role to play #mdssm

[Jeremy Ramdial @Jeremy_Ramdial]

Dr Uday Popat presenting data on the role of SCT for patients with Int and High risk MDS. #MPNsm #MDS #SOHO2025 @MDAndersonNews

[Jeremy Ramdial @Jeremy_Ramdial]

Please stop by poster CT 654 tonite at 6:30pm to discuss with Dr @dr_PrakhyathS his meta-analysis comparing two Cellular therapy options for patients with #MMsm .
#SOHO2025 @SocietyofHemOnc

[Dr. Chokri Ben Lamine @abouabdrahman0]

🔬 HCT in MDS – Holistic Decision Process (SOHO 2025)

🧩 Decision factors:
•⚰️ Mortality
•🏥 Morbidity
•🧬 Prognosis
•🧑‍⚕️ Patient views
•🎂 Age & comorbidities
•🧑‍🤝‍🧑 Donor availability

📊 Key insights (IPSS-M based):
•Early transplant benefits Moderate-high, High, and Very High risk MDS patients.
•Age matters → younger (<55y) benefit most, but even 55–65y group shows survival advantage.
•Some Low/Moderate-low risk may benefit if:
•Progressive cytopenias
•Transfusion dependence
•Failure of HMA

⚠️ Limitations: retrospective data, need for prospective validation.

#MDS #BMT #Transplant #IPSSM #soho25

[NEJM @NEJM]

Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: https://t.co/ZCfkG7tpBI

[Hagop Kantarjian,MD @DrHKantarjian]

Out in @Ajhematology: Relapse mechanisms after frontline FLT3 inhibitor therapy in FLT3 #AML include FLT3 loss and emergent non-FLT3 mutations. Post-relapse outcomes are poor, especially in FLT3 mut relapses.
@NicholasShortMD #Leukemia
https://t.co/8K2PjLG3ld
#leusm

[Fadi Haddad, MD @FadiHaddad_MD]

Survival of adult #ALL is significantly better 👍

‼️ Ph ➖ ALL: Adding antibodies &amp; immunotherapy is crucial, in frontline &amp; salvage

‼️ Ph➕ ALL: Chemotherapy-free approach improves survival &amp; spares transplant

#leusm @DrHKantarjian @SocietyofHemOnc @OncoAlert

[Survivor's Cancer Action Network - SCAN @SurvivorsCANLA]

We're proud to support @lcalsfeld for LLS Visionary of the Year! ❤️

A true advocate for the cancer community, Clark is making a difference—and there’s still time to support his campaign before June 14!

Donate here: https://t.co/mAeW48ah0x

#CancerAdvocacy #VisionaryOfTheYear

[Anirban Maitra @Aiims1742]

Familiar face on Houston’s highways 🛣️
@lab_rezvani @MDAndersonNews

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our

[Hind Rafei @HindRafei]

🧵1/
T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓.

📄Link: https://t.co/LuzFWmSsPK

I’m so thrilled🥳to share our work out now🚨@Nature identifying🔎CREM as a central intracellular checkpoint🚦in #CARNK cells.

Let me tell you a story...👇🏼

[Fadi Haddad, MD @FadiHaddad_MD]

Discussing the latest updates in Chronic Myeloid Leukemia #CML at HemOnc Pulse meeting

✅ Looking for ways to improve #patient outcomes &amp; access to treatment

✅ Panel discussion &amp; insights on next steps in the field

✅ Connecting with colleagues &amp; friends

#HOPlive25 #leusm

[UT MD Anderson @UTMDAnderson]

@ASCO @Jeremy_Ramdial @JessSonMD @ShannonWestin Dr. @Jeremy_Ramdial shared details of a Phase II study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies that began enrolling in December 2024. @ASCO #ASCO25 #EndCancer

[Jeremy Ramdial @Jeremy_Ramdial]

Was very excited to see all the interest in our off-the-shelf NK cell therapy given in combination with Allogeneic stem cell transplant for patients with high-risk AML. For many patients this was their second SCT and many others had TP53 mutated. Indicating high risk. #ASH24 #AML

[UT MD Anderson @UTMDAnderson]

The all-oral combination of revumenib with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) results in high remission rates in patients with relapsed/refractory AML with certain genetic mutations, our Dr. @GhayasIssa reported. #ASH24 #EndCancer

[AML Hub @AML_Hub]

CONGRESS | #ASH24 | PRESENTATION
@GhayasIssa @MDAndersonNews presents results from the phase I/II SAVE trial of revumenib plus ASTX727 and venetoclax in pediatric and adult patients with R/R AML.
This all-oral regimen demonstrated high response rates, with an ORR of 82%, and an acceptable safety profile in heavily pretreated patients with R/R KMT2Ar, NPM1 mutated, or NUP98r AML.
Follow our live feed for more updates: https://t.co/pPhObQXy6D
#leusm #AMLsm #MedicalCongress

[Jeremy Ramdial @Jeremy_Ramdial]

@MeeraMohanMD @HadidiSamer @UAMSMyeloma @rajshekharucms @MansiShahMD @nishi_shah_ Thank you Dr Mohan!